India Pharma Exports Cross 31 Billion USD Despite Global Slowdown

India’s pharma exports crossed the $31 billion mark in FY26 despite a challenging global business environment and slower demand in some international markets. The strong growth highlights the resilience of the Indian pharmaceutical industry, which continues to play a major role in supplying affordable medicines, vaccines, and generic drugs across the world.

According to industry data, India’s pharmaceutical exports touched nearly Rs 2.86 lakh crore during the financial year. Strong demand from markets such as the United States, Europe, Africa, and other emerging economies helped maintain export momentum throughout the year.

Even with the overall growth, the sector faced pressure in the final months of FY26. Pharmaceutical exports in March reportedly fell by around 23 percent compared to the same period last year. Industry experts linked the decline to lower shipments to the US and China, along with inventory buildup in the American market ahead of expected tariff-related disruptions.

Despite the temporary slowdown, exports improved compared to February levels, suggesting that global demand may gradually stabilize in the coming months. Vaccines remained one of the fastest-growing export categories, further strengthening India’s position in the global healthcare supply chain.

Also Read: Emcure Pharmaceuticals Q4 Profit Jumps 24% to Rs 243.74 Cr

Government initiatives, including the Production Linked Incentive (PLI) scheme for pharmaceuticals and bulk drugs, also supported the sector’s performance during the year. These policies encouraged domestic manufacturing, reduced dependence on imports, and attracted investments into advanced drug development and specialty medicines.

Indian pharmaceutical companies are increasingly focusing on research and development, innovation, and regulatory approvals in high-value international markets. Many firms are also expanding into biosimilars, complex generics, and specialty therapies to strengthen their long-term global presence.

Industry analysts believe the sector’s ability to adapt to changing global conditions will remain crucial in the coming years. While geopolitical uncertainties, pricing pressure, and supply chain challenges continue to affect the global pharma market, India’s strong manufacturing base and growing investment in healthcare innovation are expected to support future export growth.

The latest export numbers once again underline India’s importance as one of the world’s leading pharmaceutical manufacturing hubs.